3-(Dihydroxymethyl)-3-hydroxypentanedioic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-(Dihydroxymethyl)-3-hydroxypentanedioic acid
• 化学式: C₆H₁₀O₇
• 分子量: 194.14
• InChiKey: IQXGOUBSGSYYKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• LIPID DELIVERY FORMULATIONS
  申请人：Brown Bob D.

  公开号：US20130225663A1

  公开（公告）日：2013-08-29

  The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.
• Carbondisulfide Derived Zwitterions
  申请人：Daly Thomas P.

  公开号：US20170129853A1

  公开（公告）日：2017-05-11

  Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.
• US9320798B2
  申请人：——

  公开号：US9320798B2

  公开（公告）日：2016-04-26
• US9580385B2
  申请人：——

  公开号：US9580385B2

  公开（公告）日：2017-02-28
• [EN] LIPID DELIVERY FORMULATIONS<br/>[FR] FORMULATIONS D'ADMINISTRATION DE LIPIDE
  申请人：DICERNA PHARMACEUTICALS INC

  公开号：WO2011109294A1

  公开（公告）日：2011-09-09

  The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.